Market Research Logo

Global Oncology Biosimilars Market 2016-2020

About Oncology Biosimilars

Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes.

Technavio’s analysts forecast the global oncology biosimilars market to grow at a CAGR of 31.76% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global oncology biosimilars market for the period 2016-2020. To calculate the market size, the report considers revenue generated from the sales of biosimilars used to treat cancer.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Oncology Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche
  • Hospira
  • Mylan
  • Sandoz
Other prominent vendors
  • AbbVie
  • Allergan
  • Amgen
  • AstraZeneca
  • Baxter
  • Biogen
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Cipla
  • Coherus BioSciences
  • Coherus BioSciences
  • Daiichi Sankyo
  • Emcure Pharmaceuticals
  • GlaxoSmithKline (GSK)
  • Intas Pharmaceuticals
  • Merck
  • Pfizer
  • Sanofi
  • 3SBio
  • Wockhardt
Market driver
  • Rise in number of patent expiries
  • For a full, detailed list, view our report
Market challenge
  • Risks related to failure of drugs in the market
  • For a full, detailed list, view our report
Market trend
  • Emergence of biosimilars
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Oncology Biosimilars Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Oncology Biosimilars Market: Biocon, Celltrion, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, Hospira, Mylan and Sandoz.

Other Prominent Vendors in the market are: AbbVie, Allergan, Amgen, AstraZeneca, Baxter, Biogen, BioXpress Therapeutics, Boehringer Ingelheim, Cipla, Coherus BioSciences, Coherus BioSciences, Daiichi Sankyo, Emcure Pharmaceuticals, GlaxoSmithKline (GSK), Intas Pharmaceuticals, Merck, Pfizer, Sanofi, 3SBio and Wockhardt.

Commenting on the report, an analyst from Technavio’s team said: “It is expected that the trend of outsourcing drug manufacturing to developing countries to have a significant impact on the market. Outsourcing the production of biosimilars reduced the overall cost of manufacturing biosimilars, making them affordable.”

According to the report, a number of biological patents are either about to expire during the forecast period or have already expired. The patent expiries of branded drugs results in the entry of less expensive biosimilars, boosting the market growth.

Further, the report states that the risk related to the failure of the drugs and the high investment needed during the developmental stage hampers the growth of the market.

Companies Mentioned

Biocon, Celltrion, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, Hospira, Mylan, Sandoz, AbbVie, Allergan, Amgen, AstraZeneca, Baxter, Biogen, BioXpress Therapeutics, Boehringer Ingelheim, Cipla, Coherus BioSciences, Coherus BioSciences, Daiichi Sankyo, Emcure Pharmaceuticals, GlaxoSmithKline (GSK), Intas Pharmaceuticals, Merck, Pfizer, Sanofi, 3SBio ,Wockhardt.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Global biosimilars and oncology biosimilars market 2015
  • Overview of cancer
    • Epidemiology
      • Table Cancer burden in European Union (EU)
      • Table Global incidence of cancer 2015
      • Table Global mortality of cancer type 2015
      • Table Estimated numbers of cancer survivors by age in US 2014
    • Economic burden of cancer
  • Biosimilars industry
    • Table Definition of biosimilars in different regions
    • Comparison between biosimilars and generic small molecules
      • Table Comparison between biosimilars and generic small molecules
    • Factors influencing biologics and biosimilars
      • Table Factors influencing biologics and biosimilars
      • Table Impact of biosimilars cost savings on various sectors
    • Biosimilars: business and pricing strategy
      • Table Factors affecting success of biosimilars
      • Table Biosimilars industry: Point-of-view
    • Factors affecting the uptake of biosimilars
      • Table Factors affecting the uptake of biosimilars
    • Biosimilar opportunities
      • Table Strategic factors for new entrant
    • Growth of biosimilars 2014- 2020
      • Table Growth of biosimilars
    • Market penetration of originators and biosimilars in different regions
      • Table Share of biosimilars in recombinant drugs sales in major markets 2014
    • Current and future trends in global oncology biosimilars market
      • Table Trends in global oncology biosimilars market
    • Challenges for new entrants
      • Table Challenges for new entrants
  • Global pharmaceutical market
    • Market size and forecast
      • Table Global pharmaceutical market 2015-2020 ($ trillions)
    • Global biosimilars market
      • Table Global biosimilars market 2015-2020 ($ billions)
      • Table Number of approved biosimilars in regulated and semi-regulated markets
      • Table Global pharmaceutical, biosimilars, and oncology biosimilars market 2015 ($ billions)
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global oncology biosimilars market 2015-2020 ($ billions)
      • Table Global oncology biosimilars market overview
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by end-user
    • Hospitals
    • Retail pharmacies
      • Table Oncology biosimilars market segmentation by end-user 2014
  • Market segmentation by application
    • Table Global oncology biosimilars segmentation by application
    • Cancer treatment drugs
    • Supportive care drugs
      • Table Oncology biosimilars by application
  • Geographical segmentation
    • Global oncology biosimilar drugs market by geographical segmentation 2015-2020
      • Table Global oncology biosimilars market by geographical segmentation 2015
      • Table Global oncology biosimilars market revenue by geography 2015-2020 ($ billions)
    • Oncology biosimilars market in EMEA
      • Table Oncology biosimilars market in EMEA 2015-2020 ($ billions)
    • Oncology biosimilars market in APAC
      • Table Oncology biosimilars market in APAC 2015-2020 ($ billions)
    • Oncology biosimilars market in Americas
      • Table Oncology biosimilars market in Americas 2015-2020 ($ billions)
      • Table Global oncology biosimilars market: YoY revenue and growth based on geography 2015-2020 ($ billions)
  • Key leading regions
    • Table Key leading regions
    • US
      • Table Pharmaceutical R&D expenditure in US 2010-2015 ($ billions)
      • Table Approvals of biologicals versus biosimilars via PHSA
      • Table Approval process for biosimilars in US
      • Table Benefits of biosimilars to US healthcare system
      • Table Role of stake holders
      • Table SWOT analysis
    • Europe
      • Table Oncology biosimilars approved by EMA in Europe
      • Table Guidelines for biosimilars in EU
      • Table Time line of biosimilars in Europe
      • Table Key stake holders
      • Table Key drivers and restraints
      • Table Biosimilar industry challenges in Europe
      • Table SWOT analysis
    • Japan
      • Table Biosimilars approved by PMDA in Japan
      • Table Review process for biosimilars in Japan
      • Table Drivers and challenges in oncology biosimilars market in Japan
      • Table SWOT analysis
    • India
      • Table Biosimilars approved in India
      • Table Timeline for development of biosimilars in India
      • Table Challenges and strategies
      • Table Major domestic and international vendors operating in India
      • Table Drivers and challenges
      • Table SWOT analysis
    • China
      • Table Top domestic and international vendors operating in China
      • Table Drivers and challenges
      • Table SWOT analysis
  • Market drivers
    • Rise in number of patent expiries
      • Table Patent expiries of oncology biologics in US and EU 2020
    • Increase in prevalence of cancer
      • Table Global incidence of cancer 2015 and 2020
    • Growing aging population
    • Promising drug pipeline
    • Need for cost-effective treatment
    • Favorable government regulations
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Risks related to failure of drugs in market
    • Multiple manufacturing complexities
    • Reluctance among physicians to prescribe biosimilar products
    • Complicated regulatory process
    • Limited availability of biosimilar products
    • Risk of side effects
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Emergence of biosimilars
    • Outsourcing of biosimilar manufacturing activities
    • Rising number of strategic collaborations
    • Increase in cancer awareness
    • Rise in R&D
  • Vendor landscape
    • Competitive scenario
      • Table Global competitive landscape 2015
    • Biocon
      • Table Biocon: Key takeaways
    • Celltrion
      • Table Celltrion: Key takeaways
    • Dr. Reddy's Laboratories
      • Table Dr. Reddy's Laboratories: Key takeaways
    • F Hoffmann-La Roche
      • Table F. Hoffmann-La: Key takeaways
    • Hospira
      • Table Hospira: Key takeaways
    • Mylan
      • Table Mylan: Key takeaways
    • Sandoz
      • Table Sandoz: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report